DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,578 JPY | +3.32% |
|
+2.46% | +44.06% |
| May. 28 | RevolKa Signs Master Service Agreement with Daiichi Sankyo | CI |
| May. 27 | AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients | DJ |
| Sales 2024 | 1,602B 10.18B | Sales 2025 * | 1,772B 11.26B | Capitalization | 10,693B 67.93B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.28B | Net income 2025 * | 197B 1.25B | EV / Sales 2024 | 5.38 x |
| Net cash position 2024 | 545B 3.47B | Net cash position 2025 * | 684B 4.34B | EV / Sales 2025 * | 5.65 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
54.2
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.08% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +3.32% | ||
| 1 week | +2.46% | ||
| 1 month | +3.99% | ||
| 3 months | +12.14% | ||
| 6 months | +39.45% | ||
| Current year | +44.06% |
1 week
5 287.00
5 656.00
1 month
5 194.005 656.00
Current year
3 847.005 656.00
1 year
3 566.005 656.00
3 years
1 981.005 656.00
5 years
1 731.005 656.00
10 years
518.675 656.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 19 M€ | +11.22% | ||
| 4.18% | 240 M€ | +17.47% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 14 M€ | +18.47% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 5,578 | +3.32% | 10,016,000 |
| 24-05-30 | 5,399 | -0.97% | 4,046,800 |
| 24-05-29 | 5,452 | -0.78% | 3,633,300 |
| 24-05-28 | 5,495 | -2.35% | 4,289,300 |
| 24-05-27 | 5,627 | +3.36% | 3,000,200 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,578
JPY
Average target price
5,977
JPY
Spread / Average Target
+7.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.06% | 66.06B | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- 4568 Stock
